Tech Company Financing Transactions
Delfi Diagnostics Funding Round
On 1/18/2021, Delfi Diagnostics raised $100 million in Series A funding from OrbiMed, AV8 Ventures and Cowen Capital Partners.
Transaction Overview
Company Name
Announced On
1/18/2021
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Proceeds Purpose
Delfi plans to use this round of funds to expand its team of cancer researchers and machine learning experts and to validate its novel next-generation liquid biopsy technology through multiple prospective clinical studies.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
301 W. 29th St.
Baltimore, MD 21211
USA
Baltimore, MD 21211
USA
Phone
Website
Email Address
Overview
Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types. Leveraging recent advances in cancer biology and machine learning, DELFI's technology can achieve high performance from low-cost, widely available sequencing technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Victor Velculescu
Chief Financial Officer
William Stevens
Chief Operating Officer
Jenn Buechel
Chief Scientific Officer
Nic Dracopoli
VP - Regulatory Affairs
Mya Thomae
Browse more venture capital transactions:
Prev: 1/18/2021: Picky venture capital transaction
Next: 1/18/2021: You & Mr. Jones venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs